Cullinan Therapeutics Shares Are Trading Higher. The Company This Week Announced That Clinical Data From Its Phase 1 Trial of CLN-619 in Patients With Advanced Solid Tumors Will Be Presented at the 2024 ASCO Annual Meeting.
Cullinan Therapeutics Shares Are Trading Higher. The Company This Week Announced That Clinical Data From Its Phase 1 Trial of CLN-619 in Patients With Advanced Solid Tumors Will Be Presented at the 2024 ASCO Annual Meeting.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.